Didier Letourneur at the French Parliament

Capture-d’écran-2015-04-30-à-17.22.23-1024x574Over the next five years, a large number of biological drug patents will fall into the public domain. Already, many pharmaceutical companies develop and put on the drug market “Biosimilars” on the same pattern as for the generic chemical drugs. Because substantial savings are expected with this interchangeability, a public audition was held at the French Parliament on 29 January 2015. Didier Letourneur was one the experts that the Committee invited to this session.